Discovery of Hybrid Purine-quinoline Molecules and Their Cytotoxic Evaluation

Author(s): Khushal M. Kapadiya, Ranjan C. Khunt*

Journal Name: Letters in Drug Design & Discovery

Volume 16 , Issue 1 , 2019

DOI : 10.2174/1570180815666180419151742

  Journal Home
Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Apart from the “hit drugs”, there are many others being studied for their potent activity against several hostilities. To date, anticancer research has been exploited on the inherent versatility and active core skeleton of the compounds. Literature suggests that nitrogen rich molecules are most active and found in their potent cancer activity. Purine-based compounds such as olomoucine and roscovitine, which contain other heterobicyclic ring systems, are useful for the cell proliferation inhibitors in the treatment of many types of cancer.

Methods: We put forward the novel purine based compounds, aryl amino-quinoline-purine by a two-step procedure. In the first step, nitrogen rich molecule was synthesized by the coupling of 2,6- dichloropurine with 3-aminoquinoline in an acidic reaction conditions at the C-6 position of purine. Aryl amines were introduced at the C-2 position by acid catalyst and using polar solvent at comparatively higher reaction conditions to furnish the desired products.

Results: Stereochemical aspect was introduced for the identification of attachment of 3- aminoquinoline at the C-2/ C-6 position of purine and it was concluded by the spectral analysis (HMBC spectrum). The spectral data revealed that the first chloro-amine coupling was directed at the C-6 position rather than C-2 and the second chloro-amine coupling by various aryl amines were directed at the C-2 position. The applications of synthesized compounds were identified by their cytotoxic study against NCI-60 cell-lines. Out of nine selected molecules by NCI, 5a has shown promising response in a single dose study and GI50 value, 7.57 µM indicated that it has 7.57% lethality over HOP-92 cell-line (non-small cell lung cancer panel).

Conclusion: Two straightforward novelties were introduced, first stereochemical identification for chloro-amine coupling in purine either at the C-2 or C-6 position on the basis of HMBC spectrum. And a second type of uniqueness was to identify better anti-cancer agents out of synthesized scaffolds. Overall study shows that compound 5a is a novel therapeutic agent after modification for the treatment of non-small cell lung and it satisfied determined threshold growth inhibition criteria at a single dose level.

Keywords: Cytotoxic study, C-N coupling, HMBC, nucleosides, purine, therapeutic agents.

[1]
Martins, P.; Jesus, J.; Santos, S.; Raposo, L.R.; Rodrigues, C.R.; Baptista, P.V.; Fernandes, A.R. Heterocyclic anticancer compounds: Recent advances and the paradigm shift towards the use of nanomedicine’s tool box. Molecules, 2015, 20, 16852-16891.
[2]
Yi-Fong Chen, Y.; Lin, Y.; Morris-Natschke, S.L.; Wei, C.; Shen, T.; Lin, H.; Hsu, M.; Chou, L.; Zhao, Y.; Kuo, K.; Lee, K.; Huang, L. Synthesis and SAR studies of novel 6,7,8-substituted 4-substituted benzyloxyquinolin-2(1H)-one derivatives for anticancer activity. Br. J. Pharmacol., 2015, 172, 1195-1221.
[3]
Vitaku, E.; Smith, D.T.; Njardarson, J.T. Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA approved pharmaceuticals. J. Med. Chem., 2014, 57, 10257-10274.
[4]
aGomtsyan, A. Heterocycles in drugs and drug discovery. Chem. Heterocycl. Compd., 2012, 48, 7-10.
bAlvárez-Builla, J.; Barluenga, J. Heterocyclic compounds: An introduction. Mod. Heterocycl. Chem., 2011, 1, 1-9.
[5]
Jorda, R.; Havlicek, L.; McNae, I.W.; Walkinshaw, M.D.; Voller, J.; Sturc, A. Pyrazolo[4,3-d]pyrimidine bioisostere of roscovitine: evaluation of a novel selective inhibitor of cyclin-dependent kinases with antiproliferative activity. J Med Chem., 2011, 54, 2980-2993. (b) Banh, T.N.; Kode, N.R.; Phadtare, S. Aryl and acyclic unsaturated derivatives of thioguanine and 6-mercaptopurine: Synthesis and cytotoxic activity. Lett. Drug Des. Discov., 2011, 8, 709-716.
[6]
Sharma, V.L.; Paul, K. Synthesis and evaluation of novel N, N-disubstituted benzimidazolium bromides salts as antitumor agents. Eur. J. Med. Chem., 2015, 93, 414-422.
[7]
Vikrant, V.; Sharma, P.; Dhiman, S.; Noolvi, M.N.; Patel, H.M.; Bhardwaj, V. Small hybrid heteroaromatics: Resourceful biological tools in cancer research. RSC Advances, 2017, 7, 28313-28349.
[8]
aJadeja, Y.; Kapadiya, K.; Shah, A.; Khunt, R. Importance of HMBC and NOE 2D NMR techniques for the confirmation of regioselectivity. Magn. Reson. Chem., 2016, 54, 75-80.
bKapadiya, K.; Jadeja, Y.; Khunt, R. Synthesis of purine based triazoles by copper (I)-catalyzed huisgen azide-alkyne cycloaddition reaction. J. Heterocycl. Chem., 2018, 55(1), 199-208.
[9]
Kapadiya, K.; Pandya, M.; Rathod, C.; Dhaduk, B. Anti-cancer investigation of newly derived alicyclic ring and morpholine supported hybrid molecules by industrially viable route. J. Scient. Indust. Res., 2018, 77, 402-409. (b) Kapadiya, K.M.; Kavadia, K.M.; Manvar, P.A.; Khunt, R.C. Synthesis of nitrogen and oxygen based pyrazole derivatives and its antitubercular and antimicrobial activity. Antiinfect. Agents, 2015, 13(2), 129-138.
[10]
Kapadiya, K. Synthesis and pharmacological studies of some new heterocyclic entities. Ph.D. Dissertation, Saurashtra University, Gujarat, India. 2017.
[11]
Boyed, M.; Paull, K. Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen. Drug Dev. Res., 1995, 34, 91-109.
[12]
Ciszewski, L.; Waykole, L.; Prashad, M.; Repić, O. A Practical synthesis of 2-arylamino-6-alkylaminopurines from 2,6-dichloropurine. Org. Process Res. Dev., 2006, 10(4), 799-802.
[13]
Al-Suwaidan, I.A.; Abdel-Aziz, N.I.; El-Azab, A.S.; El-Sayed, M.A.; Alanazi, A.M.; El-Ashmawy, M.B.; Abdel-Aziz, A.M. Antitumor evaluation and molecular docking study of substituted 2-benzylidenebutane-1,3-dione, 2-hydrazonobutane-1,3-dione and trifluoromethyl-1H-pyrazole analogues. J. Enzyme Inhib. Med. Chem., 2015, 30(4), 679-687.
[14]
NCI-60 Screening Methodology, NCI 60 Cell One-Dose Screen. Available from:. https://dtp.cancer.gov/discovery_development/nci-60/methodology.htm (Accessed on April 16, 2018).


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 1
Year: 2019
Page: [21 - 28]
Pages: 8
DOI: 10.2174/1570180815666180419151742
Price: $65

Article Metrics

PDF: 31
HTML: 2



Related Article(s)

Most Downloaded Article(s)